Peng GQ, Song HC, Chen WY. Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report. World J Clin Oncol 2024; 15(7): 945-952 [DOI: 10.5306/wjco.v15.i7.945]
Corresponding Author of This Article
Wan-Yi Chen, MSc, Associate Chief Pharmacist, Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. wanyichen_cquch@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jul 24, 2024; 15(7): 945-952 Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.945
Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report
Gui-Qin Peng, Hai-Chi Song, Wan-Yi Chen
Gui-Qin Peng, Hai-Chi Song, Wan-Yi Chen, Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China
Co-first authors: Gui-Qin Peng and Hai-Chi Song.
Author contributions: Peng GQ and Song HC contributed equally to manuscript writing and editing, and data collection; Chen WY contributed to conceptualization and supervision. All authors read and approved the final manuscript. Peng GQ and Song HC contributed equally to this work as co-first authors.
Supported byWu Jieping Medical Foundation, No. 320.6750.2022-20-25; and Chongqing Health Commission, No. [2020]68.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wan-Yi Chen, MSc, Associate Chief Pharmacist, Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. wanyichen_cquch@163.com
Received: March 11, 2024 Revised: May 21, 2024 Accepted: June 5, 2024 Published online: July 24, 2024 Processing time: 126 Days and 21.7 Hours
Abstract
BACKGROUND
Epidermal growth factor receptor (EGFR) mutation and c-ros oncogene 1 (ROS1) rearrangement are key genetic alterations and predictive tumor markers for non-small cell lung cancer (NSCLC) and are typically considered to be mutually exclusive. EGFR/ROS1 co-mutation is a rare event, and the standard treatment approach for such cases is still equivocal.
CASE SUMMARY
Herein, we report the case of a 64-year-old woman diagnosed with lung adenocarcinoma, with concomitant EGFR L858R mutation and ROS1 rearrangement. The patient received two cycles of chemotherapy after surgery, but the disease progressed. Following 1-month treatment with gefitinib, the disease progressed again. However, after switching to crizotinib, the lesion became stable. Currently, crizotinib has been administered for over 53 months with a remarkable treatment effect.
CONCLUSION
The efficacy of EGFR tyrosine kinase inhibitors and crizotinib was vastly different in this NSCLC patient with EGFR/ROS1 co-mutation. This report will aid future treatment of such patients.
Core Tip: Over the past two decades, molecular targeted therapies have improved clinical outcomes significantly for non-small cell lung cancer (NSCLC) patients with either epidermal growth factor receptor (EGFR) mutation or c-ros oncogene 1 (ROS1) fusion. Nevertheless, EGFR/ROS1 co-mutation is a rare event in NSCLC, and the standard treatment for such cases is still equivocal. We report an EGFR/ROS1 co-mutation in an NSCLC patient who remained clinically stable after 53 months of treatment with crizotinib. This is the longest progression-free survival reported in the literature. This case suggested that crizotinib may be a potential choice for NSCLC patients with such EGFR/ROS1 co-mutations.
